VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Completed "ALO-IIT-012(PEAK study)", without major │ Completed "ALO-IIT-012(PEAK study)", without major │     100 │
│ protocol deviations                                │ protocol deviations                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Male, or female, 19 years to 75 years              │ Male, or female, 19 years to 75 years              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Female with childbearing potential who has a       │ Female with childbearing potential who has a       │     100 │
│ negative urine pregnancy test result at study      │ negative urine pregnancy test result at study      │         │
│ start and willing to continue practice appropriate │ start and willing to continue practice appropriate │         │
│ birth control during the entire duration of study  │ birth control during the entire duration of study  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects completed PEAK can be included within 30  │ Subjects completed PEAK can be included within 30  │     100 │
│ days after End Of the Study                        │ days after End Of the Study                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjects completed PEAK can be included if their   │ Subjects completed PEAK can be included if their   │     100 │
│ treatment is the same as randomized even after 30  │ treatment is the same as randomized even after 30  │         │
│ days of End Of the Study                           │ days of End Of the Study                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant or lactating women                        │ Pregnant or lactating women                        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subject who the investigator deems inappropriate   │ Subject who the investigator deems inappropriate   │     100 │
│ to participate in this study                       │ to participate in this study                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with a history of bladder cancer or       │ Patients with a history of bladder cancer or       │     100 │
│ patients with active bladder cancer                │ patients with active bladder cancer                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with uninvestigated macroscopic hematuria │ Patients with uninvestigated macroscopic hematuria │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with genetic problems such as galactose   │ Patients with genetic problems such as galactose   │     100 │
│ intolerance, Lapp lactase deficiency or glucose-   │ intolerance, Lapp lactase deficiency or glucose-   │         │
│ galactose malabsorption, since this study drug     │ galactose malabsorption, since this study drug     │         │
│ contains lactose                                   │ contains lactose                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ eGFR(Epidermal growth factor receptor) \< 50mL/min │ eGFR(Epidermal growth factor receptor) < 50mL/min  │      99 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ AST(aspartate aminotransferase)/ALT(alanine        │ AST(aspartate aminotransferase)/ALT(alanine        │      99 │
│ aminotransaminase) \>2.5 upper limit of normal     │ aminotransaminase) >2.5 upper limit of normal      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients with cardiac failure or a history of      │ Patients with cardiac failure or a history of      │      99 │
│ cardiac failure (New York Heart Association        │ cardiac failure (New York Heart Association [NYHA] │         │
│ \[NYHA\] Stages 3 to 4)                            │ Stages 3 to 4)                                     │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═══════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                         │   Score │
╞═══════════════════════════════════╪═══════════════════════════════════════╪═════════╡
│ Must have minimum age of 19 Years │ Male, or female, 19 years to 75 years │      43 │
├───────────────────────────────────┼───────────────────────────────────────┼─────────┤
│ Must have maximum age of 75 Years │ Male, or female, 19 years to 75 years │      51 │
╘═══════════════════════════════════╧═══════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 97
Average Levenshtein Ratio of individual lines: 92.73333333333333
OverAll Ratio: 94.86666666666667
